Objective. Tranexamic Acid (TXA) is currently the only drug with prospective clinical evidence supporting its use in bleeding\ntrauma patients. We sought to better understand the barriers preventing its use and elicit suggestions to further its use in trauma\npatients in the state of Maryland. Methods. This is a cross-sectional study. Results. The overall response rate was 38%. Half of all\nparticipants reported being familiar with the CRASH-2 trial and MATTERs study. Half reported being aware of TXA as part of\ntheir institution�s massive transfusion protocol. The majority of participants felt that TXA would have a significant positive impact\non the survival of trauma patients.Amajority also felt that the use of TXAwould increase if its administration was the responsibility\nof both trauma surgeons and emergency physicians. Conclusion. Only half of responders reported being aware of TXA as being\npart of their institution�s massive transfusion protocol. Lack of awareness of the clinical data supporting its use is a major barrier.\nHowever, most trauma providers and emergency physicians do have a favorable view of TXA and support its incorporation into\nmassive transfusion protocols.We believe that more studies of this kind on both state and national level are needed.
Loading....